Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples

Wang, Hye young; Kim, Sung-Hyun; Park, Sangjung; Kim, Seungil; Jung, Dongju; Park, Kwang Hwa; Lee, Hyeyoung

doi:10.1016/j.yexmp.2014.09.011

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 90% concordance was found between the results of real-time PCR and FISH. By comparison, Olsson et al, ( 15 ) found 93% agreement between real-time PCR and FISH in a study, Wang et al, ( 7 ) 92.1%, and Gjerdrum et al, ( 18 ) reported the confirming rate of 83% in the analysis of micro-dissected tumors and suggested the use of real-time PCR as a supplement to FISH and IHC. Nistor et al, ( 17 ) conducted a similar study on borderline IHC +2 category and compared FISH and real-time PCR methods, and found 92% concordance.…”

Section: Discussionmentioning

confidence: 97%

“…Also, it is a useful marker to predict the response of patients to chemotherapy, hormonal therapy, and therapeutic anti-HER-2 antibodies ( 6 ). Trastuzumab (Herceptin) is a humanized monoclonal antibody, specifically against the extracellular domain of HER-2 protein, which is a new drug for target therapy of patients with HER-2 positive ( 7 ). Fluorescent in situ hybridization (FISH) is one of the approved methods ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer

Shandiz¹,

Fani²,

Shakeri³

et al. 2017

Iran J Pathol

View full text Add to dashboard Cite

Background: Breast cancer remains the most common and second lethal cancer in females. HER-2/neu is one of the most important amplified oncogene in breast cancer. The amplification of HER-2 is correlated with decreased survival, metastasis, and early recurrence. The amplification of HER-2/neu gene and synthesis of the protein are reported in 10%-34% of breast cancer cases associated with tumor size, advanced tumor stage, high-grade tumor, young age at diagnosis, absence of steroid hormone receptor, and lymph node involvement. Methods: Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) methods are options to evaluate HER-2 expression. The current study aimed at identifying the correlation between FISH and real-time polymerase chain reaction (PCR) in measuring HER-2 expression. Results: The study investigated the performance of the real-time PCR as measured against FISH method in IHC +2 borderline cases. In a total of 120 IHC 2+ samples, 58.3% were negative and 41.6% positive for HER-2 gene, confirmed by FISH as a gold standard method. The real-time PCR ratio was <1.8 for a majority (82.8%) of the tumor samples with unamplified HER-2 gene by FISH as a gold standard assay. Conclusion: Despite the fact that real-time PCR is a promising method to evaluate HER-2 over expression and a supplementary array to FISH, according to the results of the present study it cannot be utilized instead of gold standard techniques; therefore, additional studies should be carried out to appraise the value of this method to evaluate HER-2 over expression.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer

Shandiz¹,

Fani²,

Shakeri³

et al. 2017

Iran J Pathol

View full text Add to dashboard Cite

show abstract

The importance of binding kinetics and drug–target residence time in pharmacology

Knockenhauer

Copeland

2023

British J Pharmacology

View full text Add to dashboard Cite

A dominant assumption in pharmacology throughout the 20th century has been that in vivo target occupancy—and attendant pharmacodynamics—depends on the systemic concentration of drug relative to the equilibrium dissociation constant for the drug–target complex. In turn, the duration of pharmacodynamics is temporally linked to the systemic pharmacokinetics of the drug. Yet, there are many examples of drugs for which pharmacodynamic effect endures long after the systemic concentration of a drug has waned to (equilibrium) insignificant levels. To reconcile such data, the drug–target residence time model was formulated, positing that it is the lifetime (or residence time) of the binary drug–target complex, and not its equilibrium affinity per se, that determines the extent and duration of drug pharmacodynamics. Here, we review this model, its evolution over time, and its applications to natural ligand‐macromolecule biology and synthetic drug–target pharmacology.

show abstract

Fluid Force Alterations in Cultured Mammary Epithelial and Breast Cancer Cells: Applications in Breast Cancer Diagnosis

Fuh¹

2016

View full text Add to dashboard Cite

Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples

Cited by 3 publications

References 20 publications

Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer

Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer

The importance of binding kinetics and drug–target residence time in pharmacology

Fluid Force Alterations in Cultured Mammary Epithelial and Breast Cancer Cells: Applications in Breast Cancer Diagnosis

Contact Info

Product

Resources

About